Registration Number
0226U000441,
(0125U000546)
, R & D reports
Title
To substantiate the optimal terms of specific therapy for patients with newly diagnosed and recurrent pulmonary sarcoidosis
popup.stage_title
Визначити середні терміни специфічної терапії хворих на вперше діагностований симптоматичний саркоїдоз легень на підставі оцінки показників якості життя (за даними FAS та KSQ), спірометрії (FVC) та легенево-артеріальної дифузії (DLCO) з урахуванням динаміки клінічних та радіологічних симптомів.
Head
Havrysiuk Volodymyr K., д.мед.н.
Registration Date
09-01-2026
Organization
State organization "National scientific center of phthisiatry, pulmonology and allergology named after F. G. Yanovskyi National academy of medical sciences of Ukraine"
popup.description1
To substantiate the optimal terms of specific therapy for patients with newly diagnosed and recurrent pulmonary sarcoidosis, based on the assessment of indicators of quality of life, spirometry, lung diffusion capacity and the change of clinical and radiological symptoms
popup.description2
Study object – 32 patients: 16 patients with newly diagnosed stage 2 pulmonary sarcoidosis and 16 patients with recurrent stage 2 pulmonary sarcoidosis in active phase of relapse. A control group of 60 previously examined patients was used to assess the duration of specific therapy. Aim – to justify an optimal term of specific therapy in newly diagnosed and recurrent pulmonary sarcoidosis patients using quality of life assessment score, spirometry, diffusing lung capacity, clinical and radiological data. Methods – clinical, including quality of life assessment tools, chest computed tomography, lung ventilation and diffusion capacity tests, statistical methods – Spirman’s rank correlation coefficient. The use of FAS, KSQ questionnaires were proposed for a quality of life assessment in pulmonary sarcoidosis patients, and the pattern of the change of FAS/KSQ scores during the course of disease as an additional tool for decision making regarding the start or stop of the therapy. It was established that the correlation between FAS, KSQ and spiromentry, total lung capacity and diffusing lung capacity, CT-signs allowed to recommend FAS, KSQ for a correction of regimens and terms of treatment in newly diagnosed pulmonary sarcoidosis patients. It was determined that more pronounced CT signs of sarcoidosis, a grade of ventilation and diffusing lung disturbances in patients with recurrent pulmonary sarcoidosis were associated with more significant deterioration of quality of life. It was proved that using of new clinical remission criteria led to shorter terms of specific therapy in newly diagnosed pulmonary sarcoidosis patient by 7,3 weeks on average: mean duration was (34,4 ± 2,9) weeks in study group vs (41,7±1,4) weeks in control group. Sphere of application – pulmonology, phthysiology.
Product Description
popup.authors
Yaroslav O. Dziublyk
Yevhniia O. Merenkova
Nataliia V. Pendalchuk
Volodymyr K. Havrysiuk
Nataliia D. Morska
popup.nrat_date
2026-01-09
